Company Overview of Danube Pharmaceuticals, Inc.
Danube Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the research and development of drugs and technologies for the treatment of ophthalmic and other related diseases. Its DNB-001 is a small molecule for the treatment of glaucoma. The company also engages in the research of efficacy of novel oral therapy with a dual mechanism of action, in lowering the intraocular pressure ("IOP") in patients with ocular hypertension. The company was incorporated in 2005 and is based in New York, New York.
689 Fifth Avenue
New York, NY 10022
Founded in 2005
Key Executives for Danube Pharmaceuticals, Inc.
Similar Private Companies By Industry
|20n Labs, Inc.||United States|
|23andMe, Inc.||United States|
|2C Tech Corporation, Inc.||United States|
|3-V Biosciences, Inc.||United States|
|3D Bio Holdings LLC||United States|
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.
Most Searched Private Companies
|Company Name||Geographic Region|
|Lawyers Committee for Civil Rights Under Law||United States|
|NYC2012, Inc.||United States|
|Rush University||United States|
|The Advertising Council, Inc.||United States|
Sponsored Financial Commentaries
To contact Danube Pharmaceuticals, Inc., please visit --. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.